Detection of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer using circulating tumor DNA

Detection of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer using circulating tumor DNA - Circulating tumor DNA in RAS-wildtype colorectal cancer

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000034923

Enrollment

Registered

2018-11-20

Start date

2017-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with RAS-wildtype metastatic colorectal cancer who have a plan for administration of anti-EGFR antibody (performance status 0-2)

Exclusion criteria

Exclusion criteria: 1. Patients diagnosed as double primary cancer 2. Patients with hereditary cancer syndrome

Design outcomes

Primary

Measure	Time frame
Association between progression-free survival and the period from the introduction of anti-EGFR antibodies to detect genetic changes in circulating tumor DNA	—

Secondary

Measure	Time frame
Response rate, progression-free survival, overall survival, and concordance of genetic alterations between circulating tumor DNA and archival tissue Association between progression-free survival and initial amount of circulating tumor DNA Association between progression-free survival and changes in circulating tumor DNA amount 4 months after introduction of anti-EGFR antibodies	—

Countries

Japan

Contacts

Public ContactShinya Yamada

Kanazawa University Graduate School of Medicine Department of Advanced Research in Community Medicine

2nai5ken@gmail.com076-265-2255

Outcome results